Voting is NOW OPEN for the 2018 Canadian Cannabis Awards!
We are pleased to say the Medicinal Cannabis Resource Centre has been nominated as Top Clinic!
It is now up to our wonderful patients to help us win!
Go to: https://canadiancannabisawards.com/vote/
Under the ‘Products & Places’ category, select ‘Top Clinic’
Click ‘Medicinal Cannabis Resource Centre Inc.’
We want to thank each and every one of you for supporting us throughout the years.
Looking forward to many more years of assisting patients!
Winners will be announced at the CCA Gala on November 29, 2018 and posted online November 30, 2018!
So far, all the states that have legalized marijuana have done so through grassroots petitions and ballot initiatives meant to bypass risk-averse lawmakers in state houses.
California, Nevada, Maine, Massachusetts, Alaska, Oregon, and the District of Columbia have all followed Colorado and Washington either to legalize the sale and use of recreational marijuana or, at a minimum, to decriminalize possession and consumption of small amounts of the drug.
But 2018 may be a tipping point — the moment when the momentum of pot makes it impossible for state lawmakers to avoid. State legislatures are poised to begin passing marijuana reform laws next year. The taboos against smoking dope may go up in a cloud of narcotic smoke.
Lawmakers must still juggle serious public safety issues, even as they eye what they hope will be new revenue streams from pot that they don’t want flowing to neighboring states.
Vermont, Rhode Island, and New Jersey all devoted serious debate to this in 2017, and their state legislatures could send legislation to their governors next year to sign into law.
Vermont is the only state legislature to pass a legalization measure, although Democratic Gov. Phil Scott vetoed it.
With recreational use and sales opening within months in Canada and Massachusetts, neighboring states feel compelled to study and implement new public safety measures. Beyond that, however, lawmakers in these states are also emboldened by polls showing public support for recreational use.
Tom Gorman, director of the Rocky Mountain High Intensity Drug Trafficking Agency, believes 2018 could be a tipping point.
“What I was hoping was the rest of the states would say, ‘OK, we’ve got Washington, and we’ve got Colorado, let’s wait and see what happens so we can make an informed decision one way or the other,” said Gorman, whose Denver-based organization supports federal and local anti-drug policing. “Either it wasn’t as bad as the anti-marijuana folks said it was, or, ‘My God, this is disastrous, we don’t want this for our state.’”
But Gorman’s longtime adversary in the recreational legalization battle, Brian Vincente, an attorney who has been a leader in Colorado’s decades-long fight over legalization, thinks otherwise. “I think we’ve probably cleared the tipping point,” he told the Washington Examiner. “I think when California and Massachusetts came on board and legalized — I mean, California’s such a massively recognized global economy and Massachusetts, this puritanical, historic state — I think those two for me signaled that it’s the beginning of the end for prohibition.”
What develops next in pot policy is likely to be shaped by data from the early legalizers, Colorado and Washington, by how it is interpreted, by how legislatures respond to legalization as opposed to citizen ballot initiatives, and by whether the federal government will step in.
If Vermont, Rhode Island, and New Jersey make moves, and even if only one or two other voter-based initiatives passed, fewer states would remain that didn’t share border with a state with legal marijuana. Some people thought Colorado and Washington were “experiments” and would remain highly quarantined, but it was an illusion.
Getting a clear “before and after” picture of the effects of legalized marijuana isn’t easy. Some experts have suggested that a comprehensive picture could take 20 years or more to become clear because data can be affected by so many other sociological factors.
“What I hear from Colorado is that, they say, you need to wait a couple years. Because the data sets right now are very immature and we don’t really know as much as we’d like to know,” said Vermont State Rep. Scott Beck, a Republican.
Beck’s concerns about “immature” data are well-founded. For example, one of the first comprehensive studies on the effects of legalization was published by the Colorado Department of Public Safety in March, 2016. It began with a strong caution:
“It is too early to draw any conclusions about the potential effects of marijuana legalization or commercialization on public safety, public health, or youth outcomes, and this may always be difficult due to the lack of historical data. Furthermore, the information presented here should be interpreted with caution. The decreasing social stigma regarding marijuana use could lead individuals to be more likely to report use on surveys and to health workers in emergency department and poison control centers, making marijuana use appear to increase when perhaps is has not.
“Finally, law enforcement officials and prosecuting attorneys continue to struggle with enforcement of the complex and sometimes conflicting marijuana laws that remain. Thus, the lack of pre-commercialization data, the decreasing social stigma, and challenges to law enforcement combine to make it difficult to translate these early findings into definitive statements of outcomes.”
Just four months before pot sales began in Colorado, Dr. Larry Wolk became the executive director and chief medical officer for the Colorado Department of Public Health and Environment. Wolk says he’s often in contact with officials from other states and other countries, and says the number one piece of advice he gives them is usually the same, and it is about data.
“Conceptually, stop thinking about this as a ‘starting from zero’ — you know, if it’s not legalized — to some dramatic number as a result of legalization,” Wolk said. “So recognizing, what’s the base use of marijuana amongst adults and kids.
In Colorado, public safety concerns have broken along two lines: Concerns about the effects on those underage, whether it’s direct use by teens or children being born with THC detectable in their systems, and concerns about public safety on the roads, mainly because of people driving while stoned.
Perhaps nothing has confounded policymakers more than the inability to measure impairment due to marijuana use quickly in the same way a breathalyzer gauges a driver’s blood alcohol level, which is a reliable measurement of impairment. Not only does the absence of a similar testing tool make roadside analysis difficult for law enforcement, it also makes studying the issue murky as well.
Complicating those factors is the notion, which many experts say is incorrect, that marijuana “impairment” on driving can be measured like alcohol.
“Peak impairment does not occur when THC concentration in the blood is at or near peak levels,” a 2017 report by the National Highway Traffic Safety Administration noted. THC is the active compound in marijuana responsible for its psychoactive effects. “Peak THC level can occur when low impairment is measured, and high impairment can be measured when THC level is low.”
A January release by the Colorado Department of Transportation noted that traffic fatalities were up 24 percent since 2014, the first year that recreational pot was legal. But the word “marijuana” never appeared in that release, and officials never singled out any overriding factors for blame. The same release noted that those figures came during a population boom and also said, “The rise in fatalities is part of a national trend. Fatalities are up nationally by about 8 percent.”
Beck says legislators in that state have struggled with what to do about drugged driving, absent any test similar to a breathalyzer.
“Now we’re basically talking about having officers doing ‘driving under the influence’ tests roadside, which is kind of a throwback to the ’70s and ’80s, ‘walk the line, touch your nose,’” Beck said.
“It’s subjective. How’s it going to fare in a court of law? How does an officer determine whether it’s alcohol, or THC, or some other substance? We have trained many people in the state to be drug recognition experts. But I don’t think we have enough of them that people are confident that we can identify all these people.”
Especially concerning to Beck is that Vermont will have to deal with an increase in drugged drivers whether or not the state decriminalizes marijuana because tit has drivers on its roads from Massachusetts and Canada, where dope will be legal.
Effects on underage people
Supporters of legalization in Colorado have promoted a pair of studies they say show no increase in teen usage.
The state’s “Healthy Kids Colorado” survey polls 17,000 youth. From 2013 to 2015, the percentage of youth who said they had used marijuana once in the last month inched up from 20 percent to 21 percent, and that 21 percent is comparable to the national average.
Even though there was an uptick from 20 to 21 percent over two years, scientists have said this isn’t “statistically significant.”
“There’s some corridor of variability or error when you do any kind of study,” Wolk explained, “and so the reason why we say not to make much of the small increase that occurred the one year which then actually was followed by a small decrease is that, that’s within the corridor of variability that … researchers say is what’s attributed to chance.”
The other study on teen use of marijuana showed a similarly small increase, but relied on a much smaller sample.
Opponents of legalization, meanwhile, highlight statistics from a Pueblo-based hospital showing about a third of all babies tested have shown a presence of THC in their systems.
Tom Tancredo served as a congressman from Colorado for five terms, and ran for president in 2008 on a hardline immigration stance. But he lent his name and voice to pro-legalization radio ads in the run-up to the 2012 vote. He says he’s lost friends over this and says he would also support legalization again. Nevertheless, he acknowledges that lawmakers must consider secondary effects. Babies born with THC in their systems are a prime example, he says.
“I think that that should be dealt with legally,” he told the Washington Examiner. “Because I believe that’s child endangerment. And I think people should go to jail for that. Again, I don’t care what you do to yourself, as an adult, but I certainly care what you do to those who are not.”
Wolk says there is no data that proves that a mother passing THC to her baby is doing more harm, or as much harm, a mother using alcohol or tobacco during pregnancy. The studies are lacking in part because the federal government’s labeling marijuana as a “Schedule 1” drug has prevented many labs from getting the strict permissions needed to do marijuana testing.
“We know enough to say there’s not a lot in the way of short-term or acute harm if a baby is born to a THC-positive mom, but there’s likely the potential that it does affect or impact the developing brain,” Wolk said.
“So, obviously, our policy statement based on all available research we have says that pregnant mothers and breast-feeding mothers should not be using marijuana, period.”
Taxation and competition
Some state lawmakers in Vermont and Rhode Island who support either decriminalization or retail legalization often suggest that part of the “inevitability” they feel about the issue is something akin to the “domino theory” from the Cold War era. Once a single region “falls,” then so do neighboring regions. It sets off a chain reaction that can’t be stopped.
There’s also a “funding paradox” for states looking at decriminalization as opposed to full-on commercial sales and legalization. If a state decriminalizes pot rather than legalizes it and collects revenue from taxing it, it feels it’s missing out on money for road safety and education and prevention programs for youth.
“In general, our state has no taxing capacity left to run our programs, to educate our children,” said Republican Vermont State Rep. Heidi Scheuermann. “Even [former] Gov. [Peter] Shumlin said that a number of years ago, and that’s still a fact.
“So, if we’re going to create new needs, as a result of — whether it’s decrim or legalization of marijuana, we’re going to have to find some revenue somewhere to do that.
“I don’t know if it has to be done all at once, though,” she added, noting that she’s depending on a study commissioned by the governor to draw conclusions and find solutions.
Other lawmakers appear to be succumbing to the fear of missing out.
“When Massachusetts goes to a tax-and-regulate structure next year, anybody who’s interested in accessing marijuana can easily go to Massachusetts,” said Rhode Island State Sen. Joshua Miller, referring not only to the way Colorado taxes pot sales, but also oversees virtually every detail regarding cultivation and distribution, which includes tracking every plant grown with its own barcode. “Then it becomes more of, the revenue is either going to be Massachusetts’ revenue or Rhode Island’s revenue. And those that think it’s a good idea or a bad idea have a different reality to also consider.”
Miller, a Democrat, compared the potential for new tax revenues through a tax-and-regulate structure to the expansion of state lotteries in the ’80s, or casino gambling in the ’90s. When neighboring states adopt the new revenue, other states find it hard to resist.
Competitive pressures come back to Colorado. Its pot revenues, such as they are, could deflate as soon as other states legalize. So a state can be left with the costs of marijuana legalization, but see its revenue hopes dashed.
“There’s three times as many people in Los Angeles as there are in the state of Colorado. Now that California has legalized marijuana, I do think they’re going to be taking the helm in a lot of ways,” Vicente said.
Those who have opposed all movements toward new leniency with marijuana say the taxation lure will remain a Faustian bargain.
“There has been some extra [tax] money, no doubt about it,” Gorman said. “Where we missed the boat is, what is it costing us, what are the societal costs? And if you look at alcohol and tobacco, and you say ‘highly taxed products,’ the taxes only cover about 10 to 12 percent of societal costs, that’s probably not a good investment. And we don’t know that yet with marijuana. But we will down the road. And if we use illegal drugs as an example, we’d have to say the odds are it’s not going to be a good investment for us.”
The federal void
All of this state action comes in a broad federal void. Despite Attorney General Jeff Sessions’ dislike of liberalizing of marijuana laws, little action has come from the Department of Justice to roll back activities by states.
Sessions sent a letter to Colorado’s Democratic Gov. John Hickenlooper in August asking him how the state was responding to a report of increases in traffic deaths, youth consumption, and emergency room visits.
The response came not only from the Colorado governor, but the state’s Republican Attorney General Cynthia Coffman (popular in her party for joining a lawsuit against the EPA’s Clean Power Plan). She and Hickenlooper vigorously defended the state’s marijuana laws, telling Sessions, “When abuses and unintended consequences materialize, the state has acted quickly to address any resulting harms.”
Don Murphy, director of conservative outreach for the Marijuana Policy Project, a lobbying organization dedicated to ending marijuana prohibition, says the quick adoption of recreational marijuana by other states is pushing the federal government into a corner.
“The states don’t care anymore what the federal government says or doesn’t say. And so, they’re just moving along doing their own thing,” Murphy said.
Elected officials at the federal level seem uninterested in diving into the issue. The Washington Examiner reached out to representatives on Capitol Hill from Rhode Island, Vermont, and Michigan (where a ballot issue could appear in 2018), and none would comment.
Still, the nation will get a clear preview of just how far legal pot may go, and how willing states are to continue to challenge federal laws, when voters cast ballots in New Jersey this November. Voters there will choose a successor to long-time marijuana foe Gov. Chris Christie. The candidates there have drawn a clear distinction between themselves. The Democratic candidate is ready to work on loosening the state’s marijuana laws, and the Republican candidate is firmly opposed.
The legislative hurdle appears to be the most comprehensive test for supporters of legalization. If elected representatives and senators in any of these states can find compromise on a bill, and if a governor of a state feels he or she can sign such a bill into law, then supporters of legalization believe the fight against marijuana prohibition will effectively be over.
“We’re at the precipice of actually legalizing it, I believe,” said New Jersey State Sen. Nicholas Scutari, a leading advocate for adopting a retail structure based on Colorado’s. “So, we might as well be at the head of the pack instead of at the rear, like we have been on so many other issues.”
By GFarma News – October 23, 2017
Medicinal cannabis: Rational guidelines for dosing
Gregory T Carter 1*, Patrick Weydt 2, Muraco Kyashna-Tocha 3 & Donald I Abrams 4
1 Department of Rehabilitation Medicine
2 Departments of Neurology and Laboratory Medicine
University of Washington School of Medicine Seattle WA 98531 USA
Email: [email protected]
3 The Cyber Anthropology Institute Seattle WA 98145 USA
4 San Francisco General Hospital Division of Hematology/Oncology
Department of Medicine University of California San Francisco CA 94110 USA
*To whom correspondence should be addressed
IDrugs 2004 7(5):464-470
The Thomson Corporation ISSN 1369-7056
The medicinal value of cannabis (marijuana) is well documented in the medical literature. Cannabinoids, the active ingredients in cannabis, have many distinct pharmacological properties. These include analgesic, anti-emetic, anti-oxidative, neuroprotective and anti-inflammatory activity, as well as modulation of glial cells and tumor growth regulation. Concurrent with all these advances in the understanding of the physiological and pharmacological mechanisms of cannabis, there is a strong need for developing rational guidelines for dosing. This paper will review the known chemistry and pharmacology of cannabis and, on that basis, discuss rational guidelines for dosing.
Keywords Cannabinoids, cannabis, dosing, marijuana, pharmacology
Introduction and brief historical background
Possibly the first references to the medicinal use of cannabis are found in the Chinese pharmacopoeia of Emperor Shen-Nung, written in 2737 BC. This document recommended cannabis for analgesia, rheumatism, beriberi, malaria, gout and poor memory . Eastern Indian documents in the Atharvaveda, dating to about 2000 BC, also refer to the medicinal use of cannabis . Archeological evidence has been found in Israel indicating that cannabis was used therapeutically during childbirth as an analgesic . This use of cannabis continued in the West until the mid-1880s and continues today in parts of Asia. In ancient Greece and Rome, both the Herbal of Dioscorides and the writings of Galen refer to the use of medicinal cannabis .
The medicinal use of cannabis in western medicine occurred much later. There is mention of it in a treatise by Culpepperwritten in medieval times. British East India Company surgeon William O’Shaughnessy introduced cannabis for medicinal purposes into the United Kingdom following observations he made while working in India in the 1840s. He used it in a tincture for a wide range of uses, including analgesia , and Queen Victoria used cannabis for relief of
dysmenorrhea in the same era [6•]. In 1937, against the advice of the majority of the medical community and much of the American Medical Society, the federal government criminalized non-medical cannabis. Cannabis was removed from the United States Pharmacopoeia in 1942 but, up until that time, had still been prescribed by physicians .
The physiological mechanisms and therapeutic value of cannabinoids continue to be well documented in the medical literature[6•, 7, 11,12••,13,14,15••,16• ,17••,18••,19-21,22••, 23,24••,25-27,28•,29,30,31••,32-36]. However, there has been little written on appropriate dosing regimens for the medicinal use of cannabis. With current and emerging laws allowing physicians in many areas of the world to recommend the use of cannabis to treat symptoms of certain diseases and medical conditions, there is a need for medical literature describing rational dosing guidelines. This paper will review the known chemistry and pharmacology of cannabis and then, on that basis, discuss rational guidelines for dosing.
Chemistry and pharmacology of cannabis
Cannabis is a complex plant, with several existing phenotypes, each containing over 400 chemicals [14,15••]; approximately 60 are chemically unique and classified as plant cannabinoids [11,15••]. Naturally occurring cannabinoids are also produced in the human body . The cannabinoids are 21-carbon terpenes, biosynthesized predominantly via a recently discovered deoxyxylulose phosphate pathway [16••], and are lipophilic. Δ9-tetrahydro-cannabinol (THC) and Δ8-THC appear to produce the majority of the psychoactive effects of cannabis. Δ9-THC, the active ingredient in dronabinol (Marinol), is the most abundant cannabinoid in the plant and this has led researchers to hypothesize that it is the main source of the effects of the drug . Dronabinol is available by prescription as a schedule III drug.
Other major plant cannabinoids include cannabidiol and cannabinol, both of which may modify the pharmacology of THC and have distinct effects of their own. Cannabidiol is the second most prevalent active ingredient in cannabis and may produce most of its effects at moderate, mid-range doses. Cannabidiol converts to THC as the plant matures and over time this THC degrades to cannabinol. Up to 40% of the cannabis resin in some strains is cannabidiol [6•,26]. The amount varies according to plant; some varieties of Cannabis sativa have been found to contain no cannabidiol [6•]. As cannabidiol may help reduce anxiety symptoms, cannabis strains without cannabidiol may produce morepanic or anxiogenic side effects. Cannabidiol may exaggerate some of the effects of THC (including increasing THC-induced euphoria), while attenuating others, and competitively slows THC metabolism in the liver.
Consequently, a dose of THC combined with cannabidiol will create more psychoactive metabolites than the same dose of THC alone [27,31••]. In mice, pre-treatment with cannabidiol increased brain levels of THC by 3-fold and there is strong evidence that cannabinoids can increase the brain concentration and pharmacological actions of other drugs [10,11]. Some researchers have proposed that many of the negative side effects of dronabinol, including sedation and altered mental activity, could be reduced by combining it with cannabidiol or possibly other non-psychoactive cannabinoids .
Much less is known about cannabinol, although it appears to have pharmacological properties that are quite different from cannabidiol. Cannabinol has significant anticonvulsant, sedative and other pharmacological activities that are likely to interact with the effects of THC . Cannabinol may induce sleep and may provide some protection against seizures for epileptics [14,28•,32].
Two physiologically occurring lipids, anandamide (AEA) and 2-arachidonylglycerol (2-AG), have been identified as endogenous cannabinoids (endocannabinoids), although there are likely to be more . The physiological roles of these endocannabinoids have been only partially clarified but availableevidence suggests that they function as diffusible and short-lived intercellular messengers that modulate synaptic transmission. Recent studies have provided strong experimental evidence that endocannabinoids mediate signals retrogradely fromdepolarized post-synaptic neurons to presynaptic terminals to suppress subsequent neurotransmitter release, driving the synapse into an altered state [29,31••]. Signaling by the endocannabinoid system appears to represent a mechanism by which neurons can communicate backwards across synapses to modulate their inputs.
There are two known cannabinoid receptor subtypes. Subtype 1 (CB1) is expressed primarily in the brain whereas subtype 2 (CB2) is expressed primarily in the immune system[29,31••]. Cannabinoid receptors constitute a major family of G protein-coupled, seven-helix transmembrane nucleotides, are similar to the receptors of other neurotransmitters such as dopamine, serotonin and norepinephrine, and are the most abundant G protein-coupled receptor in the brain [8,10,11]. Activation of protein kinases may be responsible for some of the cellular responses elicited by the CB1receptor .
Because of this biochemical complexity, characterizing the clinical pharmacology of cannabis is challenging. Further complicating the evaluation of cannabis is the variable potency of the plant material used in research studies. The concentration of THC and other cannabinoids in cannabis varies greatly depending on growing conditions, plant genetics and processing after harvest [6•,7,8]. The highest concentrations of bioactive compounds are found in the resin exuded by the flowering female plants [6•,7,8]. Leaf mixtures of cannabis have concentrations of THC ranging from 0.3 to 4% by weight [6•,7,8]. However, cannabis today is typically distributed as flowers and can contain 8 to ≥ 25% of THC. Thus, 1 g of cannabis flowers would typically contain 80 to 250 mg of THC [6•].
The clinical pharmacology of cannabis containing high concentrations of THC may differ from plant material containing small amounts of THC and higher amounts of the other cannabinoids. Moreover, the bioavailability and pharmacokinetics of inhaled cannabis are substantially different than when cannabis is ingested [6•].
Although it is a potent drug that may produce psychoactive effects, THC (and the other cannabinoids) has relatively low toxicity, and lethal doses in humans have not been described [25,26]. The theoretical LD50 value is estimated to be 1 to 20,000 or 1 to 40,000, using a single
cannabis cigarette as a unit of dose. Conversely stated, a human would have to consume 20,000- to 40,000-fold the amount of cannabis contained in one cigarette, in a short period of time, to achieve lethality. Using this as a basis, it has been estimated that 628 kg of cannabis would have to be smoked in 15 min to induce a lethal effect .
Central effects of cannabinoids include disruption of psychomotor behavior, short-term memory impairment, intoxication, stimulation of appetite, antinociceptive actions (particularly against pain of neuropathic origin) and anti-emetic effects. Although there are signs of mild cognitive impairment in chronic cannabis users there is little evidencethat such impairments are irreversible, or that they are accompanied by drug-induced neuropathology. A proportion of regular users of cannabis will develop some tolerance . A study by Hart and co-workers demonstrated that acute cannabis smoking produced minimal effects on complex cognitive task performance in experienced cannabis users, while still subjectively providing a euphoric ‘high’ [38••]. The potential medical applications of both natural and synthetic cannabinoids are currently being tested in a number of clinical trials.
Delivery system and pharmacokinetics
The route of administration is an important determinant of the pharmacokinetics of the cannabinoids in cannabis, particularly absorption and metabolism [39-42]. Typically, cannabis is smoked as a cigarette with a mass of between 0.5 and 1.0 g. After combustion and inhalation, peak venous blood levels of 75 to 150 ng of THC per ml of plasma have been measured when smoking is finished [39,43,44]. The main advantage of smoking is rapid onset of effect and ease of dose titration. When cannabis is smoked, cannabinoids in the form of an aerosol in the inhaled smoke are absorbed and delivered to the brain rapidly, as would be expected of a highly lipid-soluble drug [41,45].
Individual smoking behavior during an experiment is difficult for a researcher to control, and smoking behavior is not easily standardized, although some research protocols for standardization of smoking have been developed . An experienced cannabis smoker can titrate and regulate dose to obtain the desired acute effects and to minimize undesired effects [46,47]. Each inhalation delivers a discrete dose of cannabinoids to the body. Inhalation volume changes with phase of smoking, tending to be highest at the beginning and lowest at the end of smoking a cigarette. Some studies found frequent users to have higher inhalation volumes than less frequent cannabis users. Heavy users could absorb as much as 27% of available THC, which maybe twice as much as an infrequent user may absorb . During smoking, as the cigarette length shortens, the concentration of THC in the remaining cannabis increases. Thus, each successive inhalation contains an increasing concentration of THC . However, up to 40% of the available THC may be completely combusted in the process of smoking and may not be biologically available. Assays of cannabinoids in blood or urine after smoking can partially quantify dose actually absorbed, but the analytic procedures are methodologically demanding [47,48].
After smoking, venous blood levels of THC fall precipitously within minutes, and an hour later they are 5 to 10% of the peak level [40,41,43,44]. Plasma clearance of THC is ≥ 950 ml/min,
which is relatively high and is essentially the rate of hepatic blood flow. However, the rapid disappearance of THC from blood is largely due to redistribution to other tissues in the body rather than cannabinoid metabolism [40,41]. Metabolism in most tissues is relatively slow. Slow release of cannabinoids from tissues and subsequent metabolism results in a long elimination half-life. The terminal half-life of THC is estimated to range from 20 h to as long as 10 to 13 days, although reported estimates vary considerably and are likely to reflect the sensitivity of the measurement assay.
Smoking anything, including cannabis, is not beneficial for the lungs and airway system [49,50]. A healthier option may be vaporization; because cannabinoids are volatile, they will
vaporize at a temperature much lower than actual combustion . Heated air can be drawn through cannabis, the active compounds will vaporize, and these can then be inhaled. Vaporization delivers the substance in a rapid manner that, like smoking, can be easily titrated to the desired effect . Theoretically, this removes most of the health hazards of smoking, although this has not yet been studied. Furthermore, there may be differing vaporization points for the individual cannabinoids. Vaporized cannabis may have differing concentrations and ratios of cannabinoids compared to smoked cannabis, although this also needs further study.
Cannabis can also be ingested orally or through a feeding tube. Orally ingested THC or cannabis has quite different pharmacokinetics than when it is inhaled. The onset of action is delayed and titration of dosing is more difficult [52-54,55•]. Maximum THC and other cannabinoid blood levels are only reached 1 to 6 h after an oral dose, with a half-life of 20 to 30 h [52-54,55•]. This is also reflected in the pharmacokinetics of dronabinol capsules, which contain only synthetic THC and none of the other cannabinoids .When orally ingested, THC is degraded in the liver to the byproduct 11-hydroxy-THC, which also has potent psychoactive effects. This metabolite occurs at a much lower concentration when cannabis is inhaled. Thus, when THC (dronabinol or cannabis) is ingested orally, more sedation occurs because of the presence of the 11-hydroxy-THCpsychoactive metabolite .
Metabolism, bioavailability and drug interactions
Some inactive carboxy metabolites have terminal half-lives of 50 h to ≥ 6 days and thus serve as markers of priorcannabis use in urine tests [55•,56]. Most of the absorbed THC dose is eliminated in feces, and 33% is eliminated in urine. THC enters enterohepatic circulation and undergoes hydroxylation and oxidation to 11-nor-9-carboxy-Δ 9-THC (9-COOH-9-THC). The glucuronide is excreted as the major urine metabolite along with 18 non-conjugated metabolites. Frequent and infrequent cannabis users are similar in the way that they metabolize THC . THC bioavailability from smoked cannabis varies greatly among individuals and also depends on the composition of the specific cannabis preparation. Bioavailability can range from 1 to 27%, with variable bioavailability resulting from significant loss of THC in side stream smoke, as well as variation in individual smoking behaviors. This includes incomplete absorption from inhaled smoke, metabolism in lung, and cannabinoid pyrolysis (ie, destruction by combustion).
Cannabinoids appear to partially inhibit the metabolism of drugs metabolized by the hepatic cytochrome P450 enzyme system [57,58,59••,60]. Thus, the absorption or clearance of other drugs taken with cannabis may be slowed or hastened depending on timing and sequence of drug ingestion and past exposure. THC is highly bound to plasma proteins (97 to 99%) and is likely to interact with other highly bound drugs because of competition for binding sites on plasma proteins [61,62].
The Food and Drug Administration (FDA) first licensed and approved dronabinol in 1986 for the treatment of nauseaand vomiting associated with chemotherapy. The indication was expanded in 1992 to the treatment of anorexia associated with weight loss in patients with AIDS wasting syndrome. In a randomized, double-blind, placebo-controlled, 6-week study involving 139 patients, dronabinol provided a statistically significant improvement in appetite and non-statistically significant trends toward improved body weight and mood, and decreases in nausea [63•]. In 1999, the United States Drug Enforcement Administration, in cooperation with the FDA, reclassified the scheduling status of dronabinol from a Schedule II (CII) to a Schedule III (CIII) controlled substance (for definitions of schedules, refer to http://www.dea.gov/pubs/csa/812.htm).
In 454 patients with cancer who received a total of 750 courses of treatment for various malignancies, dronabinol capsules provided complete or partial success in easing nausea and vomiting in 68% of patients given < 7 mg/m 2/day of dronabinol and 64% of patients given > 7 mg/m2/day of dronabinol [64••]. According to the manufacturer, Unimed Pharmaceuticals Inc, the prescribed dose of dronabinol for appetite stimulation is 2.5 mg twice-daily, to be taken before lunch and dinner. For nausea, vomiting and pain the dosing is 5 mg/m2. If the 5-mg dose is ineffective, incremental increases of 2.5 mg, up to a maximum of 15 mg, is recommended. The same dose can be taken every 2 to 4 h for a maximum of four to six doses a day. Regardless of the clinical setting in which it is prescribed, the maximum total recommended dose of dronabinol is 15 mg/m2 four- to six-times-daily or 100 to 120 mg/day .
There are a limited number of well-performed clinical trials from which to draw succinct dosing regimens. Clinical trials have typically used cannabis cigarettes supplied by the NIDA (National Institute on Drug Abuse) containing 3.5 to 4.0% of THC by weight [59••,66,67]. Recently, Abrams and co-workers conducted an open-label study in patients with confirmed HIV neuropathy with persistent neuropathic pain . All patients had prior experience of smoking marijuana but had ceased for 30 days prior to admission. After a 2-day lead-in period, patients smoked one cigarette containing 3.56% of THC three-times-daily for 7 days. A heat-capsaicin-induced experimental pain model was used to clarify the effects of THC. Marijuana smoking led to a reduction in pain score to 20/100, with ten of 16 patients experiencing a 30% reduction in average daily pain. An excellent correlation was noted in the response to the heat-capsaicin model, as 14 of 16 patients experienced a 30% reduction in the area of secondary hyperalgesia after smoking .
Wade and co-workers compared plant-derived cannabis extracts to standard treatments for neurogenic symptoms unresponsive to standard treatment in a double-blind, randomized, placebo-controlled, cross-over trial with 2-week treatment periods . The enrolled patients (n = 24) had multiple sclerosis (n = 18), spinal cord injury (n = 4), brachial plexus injury (n = 1) and limb amputation due to neurofibromatosis (n = 1). Whole-plant extracts of either THC only, cannabidiol only, a mixed cannabinoid extract of both THC and cannabidiol in a 1:1 ratio, or a matched placebo were self-administered by sublingual spray at doses determined by titration against symptom relief or unwanted effects within the range of 2.5 to 120 mg/24 h. The results demonstrated that pain relief associated with both THC and cannabidiol was significantly superior to placebo. The mixed cannabinoid extract, compared to placebo, was significantly superior in providing pain relief and improving bladder control, muscle spasms and spasticity. Side effects were rare. Three patients had transient hypotension and intoxication with rapid initial dosing of the THC extract.
Deriving dosing recommendations and guidelines
Cannabis has many variables that do not fit well with the typical medical model for drug prescribing. If the plant is used, the variations are extreme. Plants vary immensely by phenotypes, and even the time of harvest affects which cannabinoids are present and in what percentages. An individual may be much more sensitive than another, heavy smokers may experience different chemical effects than light smokers and ingestion may alter bioavailability. The bulk of the research into cannabis has primarily examined THC, the other cannabinoids have been studied to a lesser degree, while little research has been performed on combinations of cannabinoids, although this is beginning to change. These combinations are important to medicinal users of cannabis as a number of positive synergistic effects could be involved [70-72]. All of these points make it imperative that the dosing is highly individualized, so a patient-determined, self-titrated dosing model is recommended. This self-titration model is acceptable given the variables discussed above, as well as the low toxicity of cannabis. This construct
is not unique to cannabis. There are other drugs that have relatively low toxicity and high dosing limits (gabapentin being one notable example), and are titrated to effect.
To facilitate an understanding of the determination of these guidelines, an estimate of the actual amount of THC obtained by a patient when smoking different strengths of cannabis must be derived. As noted earlier, with smoking as the delivery, 40% of the active ingredients are lost in side stream or combustion, and a maximum of 27% of the remaining active ingredients can actually be absorbed by the patient. Given this, the maximum THC absorbed by a patient using 1 g of cannabis containing 10% of THC would
be 16.3 mg.
The only form of cannabinoid that is available by a formal,dose-specific prescription is dronabinol. There are too many variables in the published clinical trials and case series with raw cannabis to use those studies as a basis for deriving doses. Therefore, we will use the dronabinol prescription guidelines as published by the manufacturer and accepted by the FDA as the basis for formulating our dosing recommendations for natural cannabis. It is critical to note that dronabinol is an oral preparation and contains only THC. Most medicinal cannabis
patients use smoking as the route of delivery. As we have previously noted there are significant differences in pharmacokinetics between oral consumption and smoking. Furthermore, there are varying physiological effects when the other cannabinoid forms are present, as is the case with natural cannabis plant material. It is also not clear how the original dosing construct for
dronabinol was arrived at, although we assume it was derived from clinical testing for therapeutic benefit versus side effects. Despite these inherent limitations, these calculations do provide approximate dose equivalents by weight and are useful as long as one recognizes these.
Applying the known pharmacokinetics of cannabis, as described above, to a conservative dronabinol dosing model of 2.5 to 60 mg/day, we calculated the doses for cannabis containing particular percentages of THC (Table 1). These derived figures lie closely within the range of reported amounts. In informal surveys from patients in Washington and California (USA), the average reported consumption of cannabis by medicinal users typically ranges between 10 to 20 g of raw cannabis per week, or 1.42 to 2.86 g/day of cannabis. The average strength of medical cannabis used by the patients who reported these doses was 15% THC. Thus, these patients were actually absorbing between 34 and 68 mg/day of THC from the raw cannabis. The mean strength of medical cannabis in this study was 19% THC, which corresponds to 44 to 88 mg/day of THC actually being consumed by the patient . These figures are all within a similar range.
Table 1. Amount of cannabis calculated to contain equivalent amounts of THC to dronabinol (2.5 to 60 mg).
Amount of cannabis (g) required to obtain: % of THC in cannabis
2.5 mg of THC
10 mg of THC
30 mg of THC
60 mg of THC
Our recommended doses are further reinforced by two studies that utilized smoked cannabis in a well-documented dosing regime. Chang and co-workers studied the effects of smoked cannabis dosed at 10 mg/m2five-times-daily, which is equivalent to 87.5 mg/day of THC for an average-sized person. This would be the equivalent of 3.6 g of cannabis containing 15% of THC . Vinciguerra and co-workers studied smoked cannabis dosed at 5 mg/m2 four-times-daily, or 35 mg/day of THC for an average person. This is the equivalent of 1.4 g of cannabis containing 15% of THC . For the purposes of these calculations, we assumed an average-sized person to be 1.70 m in height with a mass of 63.6 kg and a body surface area of 1.75 m2.
These doses all fall within the medical cannabis guidelines allowed in the Canadian medical system. The Canadian medical allowance for cannabis is 1 to 12 g/day, with an average of > 5 g/day. These doses are also highly similar to the dosing range reported in a recent survey of patients who use cannabis to control symptoms of amyotrophic lateral sclerosis . Thus, despite all of the noted variables, there is remarkable consistency among our derived doses and the reported doses from a number of different sources notedhere.
A final comment should be made regarding physiological tolerance to cannabinoids. Tolerance plays a significant role in cannabis use since tolerance may develop to any of the various cannabinoids . With regard to treating chronic, intractable pain, physicians will often prescribe increasingly larger doses of long-acting opioids as patients develop tolerance. These patients are also generally prescribed fast onset, short-acting opioids for ‘breakthrough pain’. This is accepted practice, despite the fact that opioids, even in an opioid-dependent patient, have the capacity to suppress breathing to the extent of inducing respiratory arrest. Long-term cannabis users can develop tolerance but, as previously discussed, there is essentially no risk for overdose. Thus, it is conceivable that a long-term cannabis user may require significantly larger amounts of cannabis to achieve a therapeutic effect. In addition, those who ingest cannabis may also require significantly higher amounts. Until more refined and purified cannabinoid preparations are available it will not be possible to derive a more specific or exact dosing schedule.
We have outlined reasonable guidelines for dosing of medical cannabis, based on the known pharmacology. Our dosing model is primarily derived from dronabinol (THC), since that is the only clearly defined, FDA-approved dosing paradigm currently available. However, our derived dosing schedule did match reasonably well with the amounts of natural cannabis reported by medical users. In using our dosing guidelines clinicians must be aware that THC is not the only clinically useful and pharmacologically activecannabinoid. The effects of THC are clearly modulated by other cannabinoids, which may have unique effects of their own. The clinician must also be aware of patient tolerance, and differing routes of intake and delivery systems, which can affect pharmacokinetics and bioavailability. Recognizing this, we recommend that our guidelines are used as aconstruct to allow the physician and patient to develop an individual, self-titration dosing paradigm. Given the current state of the known, published pharmacology of cannabis, this is the best dosing model that can be derived.
This work is supported by Research and Training Center Grant HB133B980008 from the National Institute on Disability and Rehabilitation Research, Washington, DC, USA. The authors would like to acknowledge Dale Gieringer, Martin Martinez and Ethan Russo for their help in preparing this manuscript.
••of outstanding interest •of special interest
1. Li HL: An archaeological and historical account of cannabis in China. Econ Bot (1974) 28:437-448.
2. Indian Hemp Drugs Commission: Report of the Indian Hemp Drugs Commission, 1893-94. Government Central Printing House, Simla, India (1894).
3. Zias J, Stark H, Sellgman J, Levy R, Werker L, Breuer A, Mechoulam R: Early medical use of cannabis. Nature (1993) 363(6426):215.
4. Dioscorides P: The Greek Herbal of Dioscorides. Translated by Goodyear J, Gunther RWT. Hafner Publishing, London, UK (1968).
5. O’Shaughnessy WB: On the preparations of the Indian hemp, or gunjah (Cannabis indica): Their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Trans Med Phys Soc Bengal (1838-1840).
6. Martinez M: A brief history of marijuana. In: The New Prescription:Marijuana as Medicine. Podrebarac F (Ed), Quick American Archives, Oakland, CA, USA (2000):1-18. • This well-
referenced book provides a balanced view of historical, medical and legal issues regarding medical marijuana.
7. Fankhauser M: History of cannabis in Western medicine. In: Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential. Grotenhermen F, Russo R (Eds), The Haworth Integrative Healing Press, Oxford, UK (2002):37-49.
8. Carter GT, Weydt P: Cannabis: Old medicine with new promise for neurological disorders. Curr Opin Invest Drugs (2002) 3(3):437-440. Medicinal cannabis: Rational guidelines for dosing Carter et al 469
9. Campbell VA: Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology (2001) 40(5):702-709.
10. Valjent E, Pages C, Rogard M, Besson MJ, Maldonado R, Caboche J: Δ9 tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur J Neurosci(2001) 14(2):342-352.
11. Friedman H, Klein TW, Newton C, Daaka Y: Marijuana, receptors and immunomodulation. Adv Exp Med Biol (1995) 373:103-113.
12. Chen Y, Buck J: Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism. J Pharmacol Exp Ther(2000) 293(3):807-812. •• This study, along with references [15••], [16••], [17••], [18••], [22••] and [24••], confirms the neuroprotective effects of cannabinoids.
13. Guzman M, Sanchez C, Galve-Roperh I: Control of the cell survival/death decision by cannabinoids. J Mol Med (2001) 78(11):613-625.
14. Akinshola BE, Chakrabarti A, Onaivi ES: In-vitro and in-vivo action of cannabinoids. Neurochem Res (1999) 24(10):1233-1240.
15. Hampson AJ, Grimaldi M, Axelrod J, Wink D: Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA (1998) 95(14):8268-8273. •• This study, along with references [12••], [16••], [17••], [18••], [22••] and [24••], confirms the neuroprotective effects of cannabinoids.
16. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J: Neuroprotective antioxidants from marijuana. Ann NY Acad Sci(2000) 899:274-282. •• This study, along with references [12••], [15••], [17••], [18••], [22••] and [24••], confirms the neuroprotective effects of cannabinoids.
17. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci (1999) 19(8):2987-2995.•• This study, along with references [12••], [15••], [16••], [18••], [22••] and [24••], confirms the neuroprotective effects of cannabinoids.
18. Eshhar N, Striem S, Biegon A: HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport (1993) 5(3):237-240. •• This study, along with references [12••], [15••], [16••], [17••], [22••] and [24••], confirms the neuroprotective effects of cannabinoids.
19. Hollister LE: Marijuana and immunity. J Psychoact Drugs (1988) 20(1):3-8.
20. Carter GT, Rosen BS: Marijuana in the management of amyotrophic lateral sclerosis. Am J Hospice Palliative Care (2001) 18(4):264-270.
21. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J,Ikonomidou C, Schmid HH, Fernandez-Ruiz JJ, Hansen HS: Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.J Neurochem(2001) 78(6):1415-1427.
22. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 413(6855):527-531. •• This study, along with references [12••], [15••], [16••], [17••], [18••] and [24••], confirms the neuroprotective effects of cannabinoids.
23. Ferraro L, Tomasini MC, Cassano T, Bebe BW, Siniscalchi A, O’Connor WT, Magee P, Tanganelli S, Cuomo V, Antonelli T: Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate γ-aminobutyric acid levels. J Neurosci Res (2001) 66(2):298-302.
24. Sinor AD, Irvin SM, Greenberg DA: Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett (2000) 278(3):157-160. •• This study, along with references [12••], [15••], [16••], [17••], [18••] and [22••], confirms the neuroprotective effects of cannabinoids.
25. Young F: In the Matter of Marijuana Rescheduling Petition. US Department of Justice, DEA (1988):Docket No 86-22.
26. Gurley RJ, Aranow R, Katz M: Medicinal marijuana: A comprehensive review. J Psychoact Drugs (1998) 30(2):137-147.
27. Robson P: Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry (2001) 178:107-115.
28. Rice AS: Cannabinoids and pain. Curr Opin Invest Drugs (2001) 2(3):399-414. • An excellent review article summarizing the analgesic effects of cannabinoids.
29. Di Marzo, Bisogno T, De Petrocellis L: Endocannabinoids: New targets for drug development. Curr Pharm Des(2000) 6(13):1361-1380.
30. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ: Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. Br Med J (2001) 323(7303):16-21.
31. Pertwee RG: Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs(2000) 9(7):1553-1571. •• An excellent review article outlining the future directions for drug development in cannabinoid-based medicines.
32. Renn E, Mandel S, Mandel E: The medicinal uses of marijuana. Pharm Ther (2000) 25(10):536-524.
33. Hubbard JR, Franco SE, Onaivi ES: Marijuana: Medical implications. Am Fam Phys (1999) 60(9):2583-2588.
34. Voth EA, Schwartz RH: Medicinal applications of Δ9-tetrahydrocannabinol and marijuana. Ann Intern Med (1997) 126(10):791-798.
35. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404(6773):84-87.
36. Consroe P, Musty R, Rein J, Tillery W, Pertwee R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol (1997) 38(1):44-48.
37. Abrams DI: Medical marijuana: Tribulations and trials. J Psychoact Drugs (1998) 30(2):163-169.
38. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW: Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology (2001) 25(5):757-765. •• This study confirms the minimal side effects of cannabis use on cognitive performance, particularly in chronic users.
39. Adams IB, Martin BR: Cannabis: Pharmacology and toxicology in animals and humans. Addiction (1996) 91(11):1585-1614.
40. Pertwee RG: Sites and mechanisms of action. In: Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Grotenhermen F, Russo R (Eds), The Haworth Integrative Healing Press, Oxford, UK (2002):73-81.
41. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L: Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev (1986) 38(1):21-43.
42. Barnett G, Licko V, Thompson T: Behavioral pharmacokinetics of marijuana. Psychopharmacology (Berl) (1985) 85(1):51-56.
43. Huestis MA, Henningfield JE, Cone EJ: Blood cannabinoids. 1. Absorption of THC and formation of 11-OH-THC and THC-COOH during and after smoking marijuana. J Anal Toxicol (1992) 16(5):276-282.
44. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ: Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther (1992) 52(1):31-41.
45. Matthias P, Tashkin DP, Marques-Magallanes JA, Wilkins JN, Simmons MS: Effects of varying marijuana potency on deposition of tar and Δ9-THC in the lung during smoking. Pharmacol Biochem Behav(1997) 58(4):1145-1150.
46. Heishman SJ, Stitzer ML, Yingling JE: Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav(1989) 34(1):173-179. 470 IDrugs 2004 Vol 7 No 5
47. Herning RI, Hooker WD, Jones RT: Tetrahydrocannabinol content and differences in marijuana smoking behavior.Psychopharmacology (1986) 90(2):160-162.
48. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK: Terminal elimination plasma half-life of Δ1-tetrahydrocannabinol (Δ1-THC) in heavy users of marijuana. Eur J Clin Pharmacol (1989) 37(3):273-277.
49. Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD: Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med (1993) 158(6):596-601.
50. Benowitz NL, Jones RT: Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol (1981) 21(Suppl 8-9):214S-223S.
51. Gieringer D: Cannabis vaporization: A promising strategy for smoke harm reduction. J Cannabis Ther (2001) 1(4):153-170.
52. Jones RT, Benowitz NL, Herning RI: Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol (1981) 21(Suppl 8-9):143S-152S.
53. Kelly P, Jones RT: Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol (1992) 16(4):228-235.
54. Grotenhermen F: Effects of cannabis and cannabinoids. In: Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential. Grotenhermen F, Russo R (Eds), The Haworth Integrative Healing Press, Oxford, UK (2002):55-72.
55. Mechoulam R, Devane WA, Breuer A, Zahalka J: A random walk through a cannabis field. Pharmacol Biochem Behav (1991) 40(3):461-464. • This paper delineates many of the complexities of the cannabis plant, including variations in species subtypes.
56. Hollister LE: Interactions of cannabis with other drugs in man. In: Strategies for Research on the Interactions of Drugs of Abuse. National Institute on Drug Abuse Research Monograph 68. Braude MC, Ginzburg HM (Eds), DHHS Publication No (ADM)86-1453. Superintendent of Documents, US Government Printing Office, Washington, DC, USA (1986):110-116.
57. Fellermeier M, Eisenreich W, Bacher A, Zenk MH: Biosynthesis of cannabinoids. Incorporation experiments with 13 C-labeledglucoses. Eur J Biochem (2001) 268(6):1596-1604.
58. Rueda D, Galve-Roperh I, Haro A, Guzman M: The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol (2000) 58(4):814-820.
59. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS (2002) 16(4):543-550. •• This paper describes the hepatic metabolism of cannabinoids through the cytochrome P450 system.
60. Benowitz NL, Jones RT: Effect of Δ 9-tetrahydrocannabinol on drug distribution and metabolism: Antipyrine, pentobarbital and ethanol. Clin Pharmacol Ther (1977) 22(3):259-268.
61. Gustafson RA, Levine B, Stout PR, Klette KL, George MP, Moolchan ET, Huestis MA: Urinary cannabinoid detection times after controlled oral administration of Δ9-tetrahydrocannabinol to humans. Clin Chem (2003) 49(7):1114-1124.
62. Benowitz NL, Nguyen T, Jones RT, Herning RI, Bachman J: Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther (1980) 28(1):115-120.
63. Nelson K, Walsh D, Deeter P, Sheehan F: A phase II study of Δ9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care (1994) 10(1):14-18. • This is an important clinical trial defining the benefit of cannabis in appetite stimulation.
64. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG et al: Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 139(4):258-266. •• This is a major clinical trial examining the effects of cannabinoids in the HIV-infected population.
65. Unimed Pharmaceuticals Inc: Marinol Capsules product information package insert. (2001).
66. Kelly TH, Foltin RW, Emurian CS, Fischman MW: Effects of Δ9-THC on marijuana smoking, dose choice, and verbal report of drug liking. J Exp Anal Behav (1994) 61(2):203-211.
67. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ: Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain(2003) 102(1-2):211-216.
68. Jay C, Shade S, Vizoso H, Reda H, Petersen K, Rowbotham M, Abrams D: The effect of smoked marijuana on chronic neuropathic and experimentally induced pain in HIV neuropathy: Results of an open-label pilot study. Int Conf Retroviruses Opportunistic Infect(2004):Abs 496.
69. Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil (2003) 17(1):21-29.
70. Carlini EA, Karniol IG, Renault PF, Schuster CR: Effects of marijuana in laboratory animals and man. Br J Pharmacol (1974) 50(2):299-309.
71. Fairbairn JW, Pickens JT: Activity of cannabis in relation to its Δ9-trans-tetrahydro-cannabinol content. Br J Pharmacol (1981) 72(3):401-409.
72. Gieringer D: Medical Cannabis Potency Testing Project. Bull Multidisciplinary Assoc Psychedelic Studies (1999) 9(3):20-22.
73. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Simon RM, Rosenberg SA: Δ9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomised evaluation. Ann Intern Med (1979) 91(6):819-824.
74. Vinciguerra V, Moore T, Brennan E: Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State J Med (1988) 88(10):525-527.
75. Amtmann D, Weydt P, Johnson K, Jensen MP, Carter GT: Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care (2004) 21(2):95-104.
76. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM: Medicinal cannabis: Is Δ9-tetrahydrocannabinol necessary for all its effects. J Pharm Pharmacol (2003) 55(12):1687-1694.
MariCann expansion establishes Norfolk as primary site today, in future
Photo by Jeff Tribe
MariCann Inc. looks forward to ‘growing green with green’ in its state-of-the-art $8-million 180,000-square-foot expansion.
“This is the field of dreams,” said VP of Operations Richard Kropman, indicating a large, fenced rectangle dotted with heavy machinery.
On a drizzly January morning, the target area on the MariCann property southeast of Glen Meyer was a muddy expanse. But for what Director of Media and Investor Relations Shawn Alexander describes as a startup company in a startup industry, ambitious dreams are well on their way to reality.
“We refer to it as scaling up,” understated Alexander of a 700-per-cent expansion from the current 30,000 square-foot self-contained indoor grow, production and distribution facility.
“In eight months, you’re going to see roughly 180,000 square feet of buildings standing where that second dirt pile is,” added Kropman, pointing.
MariCann Inc. is a licenced producer under Health Canada Access to Cannabis for Medical Purposes Regulations (ACMPR), one of 23 in Ontario and 38 nationwide. Created in 2013 by a founder who believes in the therapeutic practicality and effectiveness of cannabis, the company says its expertise includes a track record of creating shareholder wealth combined with experience in the pharmaceutical sector. Although currently a private company, plans are for its listing as a public entity on the Toronto Stock Exchange.
The emergence of cannabis from black market to highly-regulated and quality-assured white market medical product with multi-billion-dollar potential is driving what MariCann CEO Ben Ward (who holds an MBA with a dual concentration in operations and finance from Bradford University School of Management in England) calls only the ‘first big new phase’ on the 97.5-acre property. There are 90 acres of buildable space in total says Ward, cradling the long-term goal of creating the largest operation in the world.
“Right in Norfolk County. Norfolk County offers all the opportunity and infrastructure to allow us to do that.”
MariCann’s roots were planted via a September, 2013 handshake deal with the former owner of a MMAR (earlier Medical Marijuana Access Regulations for smaller ‘cottage industry’ operations where patients grew their own cannabis or had it grown for them) site.
The existing MMAR facility assisted in the transition to contemporary ACMPR licensing on a property with ample access to water, electrical grid and natural gas. Combined with required facilities, Health Canada regulations create a significant financial barrier to entry into the medical marijuana business, Kropman indicating a generally accepted ballpark of $9-million, and MariCann’s own $8-million startup total.
“It’s not throwing seeds in the ground and watching money come in, it’s not easy,” says VP Information Technology and Security Stephen Lem, who has 30 years of experience including working with Fortune 500 companies DuPont, Amgen and Actavis. “It requires a lot of discipline and a lot of planning.”
MariCann began operations with roughly a dozen employees, received its licence to sell in December, 2014 and sold its first product on the 20th of that month. The operation currently employs 60 in a self-contained production, processing and distribution facility which doubled sales in its second year. Expansion was always part of long-term planning and the current phase began November 22, 2016.
“We’re moving to 205,000 square feet in total,” said general contractor Jeff Ayotte, noting the new facility will have a 30,000 square-foot nursery, equal in size to the current total. First production is scheduled for the end of March, 2018.
Employment is anticipated to rise from current levels to between 80 and 100 upon project completion says Kropman. Due to its higher-tech automated nature, a majority of the new hires will be in quality control and supervisory roles.
“It will be more operations.”
It was Ayotte who mentioned the phrase ‘growing green with green’ for a project which includes lowering carbon footprint as a design element. The possibility of installing solar panels on the production facility’s roof has been investigated says Ayotte, along with various options for the site’s operational natural gas well, including gas-fired co-gen electricity production under island (off the grid) or parallel (selling back to the grid) models.
“Energy conservation on this project is huge.”
MariCann’s No. 1 priority is producing top-quality cannabis under practices which not only meet, but exceed the high bar of standards set by Health Canada. But environmentally-responsible operations also lower significant input costs for its controlled-environment (greenhouse) agriculture base, display a leading-edge approach for Health Canada, and offer ‘green’ branding advantages for clients.
“It’s a comfort level with our customers as well,” said Ayotte.
The first expansion project’s size is only part of a story that includes evolving technology in creating consistent production of a consumable food-grade item destined for pharmacy-level processing inside a controlled but fluctuating growing environment. Ayotte touched on some of the more technical aspects of a facility that to sum up succinctly, will not rely as heavily on equipment or practices converted from other uses, but more so feature dedicated state-of-the-art cannabis-producing technology.
“It kind of puts Norfolk County on the map and sets standards for production facilities.”
The process has been assisted says Ayotte, not only by the county’s support, but its natural and human advantages.
“We have a large talent pool to draw from and support us in this expansion.”
The site is currently MariCann’s lone production facility and will remain the company’s key production facility moving forward, says Kropman.
“This is an exciting phase of the industry,” he concluded. “MariCann is looking forward to expanding in Norfolk County and being part of a long-term win-win situation.”
A study conducted at Columbia University’s Mailman School of Public Health found that there were fewer drivers killed in car crashes who tested positive for opioids in states with medical marijuana laws than before the laws went into effect.
The study is one of the first to assess the link between state medical marijuana laws and opioid use at the individual level. Findings are published in the American Journal of Public Health.
Researchers analyzed 1999-2013 Fatality Analysis Reporting System data from 18 U.S. states that tested for alcohol and other drugs in at least 80 percent of drivers who died within one hour of crashing.
They looked at opioid positivity among drivers ages 21 to 40 who crashed their cars in states with an operational medical marijuana law compared with drivers crashing in states before those laws went into effect.
There was an overall reduction in opioid positivity for most states after implementation of an operational medical marijuana law.
“We would expect the adverse consequences of opioid use to decrease over time in states where medical marijuana use is legal, as individuals substitute marijuana for opioids in the treatment of severe or chronic pain,” explained June H. Kim, MPhil, the lead author.
Among the 68,394 deceased drivers, approximately 42 percent were fatally injured in states that had an operational medical marijuana laws, 25 percent died in states before an operational law went into effect, and 33 percent died in states that had never passed a medical marijuana law.
In 1996, California was the first state to pass a voter-initiated medical marijuana law.
Since then, 22 additional states and the District of Columbia have enacted their own medical marijuana laws either by voter initiatives or through state legislation.
“The trend may have been particularly strong among the age group surveyed because minimum age requirements restrict access to medical marijuana to patients age 21 and older, and most medical marijuana patients are younger than 45,” noted Kim.
According to the authors, they would expect to see similar reductions in opioid use among older cohorts if medical marijuana is increasingly embraced by older generations.
“This study is about the possible substitution relationship between marijuana and opioids.
The toxicological testing data for fatally injured drivers lend some suggestive evidence that supports the substitution hypothesis in young adults, but not in older adults,”said Guohua Li, MD, DrPH, the senior author.
“As states with these laws move toward legalizing marijuana more broadly for recreational purposes, future studies are needed to assess the impact these laws may have on opioid use,” noted Kim.
An increase in demand without an increase in production capacity, mixed with production issues and recalls, has lead to a shortage of legal medical cannabis
The availability of dried cannabis and cannabis oil in many of Health Canada’s licensed producers has decreased dramatically in the past few weeks and even months. Increasingly, some patients are reporting a decrease in the availability of their preferred products.
A mixture of factors are contributing to the shortfall, say several industry participants — namely a dramatic increase in new people registering to access medical cannabis, combined with a lack of new approved production space to satisfy it. Production issues and recent product recalls that have forced some producers to remove product from the market also impact availability.
Based on a scan by Lift on Jan 3, of the 21 producers currently licensed for sale, only one, Mettrum, had no dried buds for sale, though they had two varieties of cannabis oil. Four of 21 producers don’t currently carry any CBD options for dried buds, either in high CBD or a 1:1 ratio with THC. In addition to these current figures, some patients are seeing products selling out quickly from their licensed producers’ online shops.
However the snapshots also show some producers with the same amount of cannabis, or more, than they had a few months ago, showing the problem is perhaps not widespread. While some producers are maintaining a consistent supply and some are increasing product options, the issue has been prominent enough to prompt at least two clinics that specialize in medical cannabis access to work on helping patients find solutions.
Lift spoke with several patients about the issue, many who were expressing their frustration on social media. Most have asked to not be named on record. A common theme among patients was the anxiety of not knowing if the strains they need will be available when they need them.
One patient who only gave his first name and age, Paul, 42, registered with Tweed. He says the issue of changing availability has been ongoing for some time.
“I have been registered with Tweed since March 2015. At first they had a tremendous amount of product. Within 6 months everything disappeared. We were told more would come and it never did. When it eventually came, it would disappear within a day. I feel like the system has let patients down.”
Paul says he hopes to begin growing his own to avoid these issues as soon as he can get authorization.
“Due to system shortcomings and no end to this problem in sight, I am going the route of self growing this year once i can find a physician that understands the situation.”
“We’ve got a lot of patients complaining about the inconsistency, first of the product. For instance, they’re going to order something that will come out that morning… it will be gone by the end of the day.” -Terry Roycroft, MCRCI
Jordan Sinclair, a spokesperson for Tweed, said the producer is increasing expansion of both their Ontario facilities and expects to address any product shortfalls very soon.
“We hear the feedback from some of our customers who would like to see more variety in the shop and we’re expanding our operations in order to meet those expectations,” says Sinclair.
“A ten-fold expansion at Tweed Farms has already been harvested, some of this harvest has already been added to the shop and other strains will be added soon, as early as this week. We’re also doubling the number of rooms in Smiths Falls and expanding our extraction capabilities to get ahead of the demand curve.”
Tweed Farms is a 350,000 sq ft greenhouse facility in Niagara-on-the-Lake, with another 25,000 sq ft of processing and storage space. This is currently the largest, fully-approved facility in Canada in terms of sq ft of approved production and sales space. They have another ~160,000 sq ft of approved production space at their Smiths Falls facility in the former Hershey Factory.
“You can predict how much you can produce in your facility with some degree of accuracy, and use the statistical history to gauge how many clients you’re able to take. That’s how we gauged to stop taking on new patients. It’s just based on how much we can produce and how much the average person consumes. Of course we’d like to supply more, but there’s a limitation of how long it takes to scale up.” -John Moeller, Broken Coast
Another patient who also asked that only her first name and age be used said that she had been registered with Mettrum until recently and had a similar experience.
“When I first registered with Mettrum, the clinic I went through encouraged me to sign up with them, and not knowing much about the cannabis program, I just took their advice,” says Anne, a marketing professional in Toronto in her early 30’s. She’s now turned to dispensaries to find cannabis to treat issues with chronic pain and insomnia.
“At first I was able to usually find the product I wanted, but very quickly I began to notice the strain I liked the most, Mettrum Red No 1 (Tahoe OG), was often not for sale. After months of this I gave up even trying, and when my prescription ended I didn’t sign up again. Now I go to a few dispensaries in Toronto. They don’t always have what I need, either, but they have far more options for me to choose from to find something else that might work.”
As of last week, Mettrum was unavailable for comment. Mettrum LTD owns 3 separate facilities, including the Agripharm brand, with a total of about 100,000 sq ft of approved production space. Canopy Growth, the parent company of Tweed Inc., has recently entered into an agreement to acquire Mettrum.
Hard to shop around
Because Health Canada rules dictate that a person can only register with one licensed producer based on one signed document from a medical professional, patients are unable to shop around effectively if their producer is out or low on product.
While you can register for additional producers with a new medical document for each one, not all doctors are willing to sign multiple documents, and some private clinics will charge an additional fee for each new registration to cover their own operating costs.
“As of August, when we got the ability for people to grow product, [new registrations have] probably jumped up to ten or eleven thousand per month signing up to these LPs, which is far faster than they anticipated and all of a sudden they’re running short on product.” – Terry Roycroft, MCRCI
One medical cannabis clinic in Ontario that specializes in medical cannabis access, Simcoe Holistic Health, recently sent out an email to their clients addressing the product shortages. In the email, the clinic notes they can assist patients in registering with a new producer in addition to their current one, or moving on from their current producer and choosing new ones.
The email also noted that this is an expected short term issue and that an increase in supply is expected soon:
“We have fielded many phone calls and emails from patients inquiring about the status with different licensed producers. While we do not know more than we have shared, we have been told that new crops at many producers are expected to come online in the first few months of 2017. The sheer growth of the program and number of patients accessing the program have exceeded the expectations of many.”
Terry Roycroft, the President of the Medical Cannabis Centre Inc. (MCRCI), a private clinic in Vancouver that specializes in helping patients navigate Canada’s medical cannabis system, says his clinic is also hearing from many patients who are frustrated by a lack of availability.
Roycroft says some producers who, when patients initially signed up, had a dozen or more options of dried buds and even oils, are now often down to just a handful of options.
“We’ve seen that and there’s a lot of reasons why that’s happened. First and foremost is some of them have seen a lack of production. We’ve seen several LPs where they used to have 20 strains and products are down to three and five now.”
Roycroft says it’s not just what’s in stock, but the consistency of what is available. Some producers may introduce a strain for sale but in such limited supply that it quickly sells out. Many patients come to rely on a specific strain or THC/CBD level and different products available from their producer may not satisfy their own needs.
“We’ve got a lot of patients complaining about the inconsistency, first of the product. For instance, they’re going to order something that will come out that morning… it will be gone by the end of the day.”
Over 100,000 registrations
The other factor is the amount of people who are actually signing up for the system. Roycroft also says it’s the massive increase in people wanting to access medical cannabis that has caught the system off guard more recently. Whereas new registrations in the MMPR in early 2015 were around 1,000 or 1,500 a month, newer figures coming out of Health Canada more recently are showing well over 5,000 or more new registrations per month.
Based on recent figures, there are now well over 100,000 registrations under the ACMPR. The program has seen constant month-to-month growth since its introduction, with patient registration increasing exponentially.
The ability for more producers to now sell oil is also noted by many as a reason for an increase in patient registration. Physicians are reportedly far more comfortable working with the standardized, titrated dosages available via cannabis oils sold under the ACMPR, making them more likely to allow their patients to access these products.
Roycroft says he has also seen this increase even more through MCRCI since the government introduced new rules in August that allow registered patients to grow their own cannabis.
“As of August, when we got the ability for people to grow product, [new registrations have] probably jumped up to ten or eleven thousand per month signing up to these LPs, which is far faster than they anticipated and all of a sudden they’re running short on product.”
Despite this, Roycroft also says he believes the issue will be short lived and that in discussing the issue with different producers, he sees production increases reflecting the uptick in patient demand.
“Virtually every one of the LPs we talk to is on target to increase their growing amounts.”
New production space
One of those producers trying to increase their capacity to take on more patients is Broken Coast Cannabis. Located in Duncan, BC, on Vancouver Island, Broken Coast was licensed to produce in early 2014 and has been selling for over two years now, but in early 2015 put a cap on new registrations because of a lack of new production space to satisfy new demand.
Broken Coast currently operates inside about 12,000 sq ft, and began construction in 2016 on an expansion that will give them another 13,000 sq ft of production space, including grow rooms, drying rooms, mother rooms, and more. The expansion will allow them to potentially double their patient capacity over time.
Broken Coast’s General Manager, John Moeller, says they made a decision early on to stop taking on new patients to ensure they could provide for those already registered.
“You can predict how much you can produce in your facility with some degree of accuracy, and use the statistical history to gauge how many clients you’re able to take. That’s how we gauged to stop taking on new patients. It’s just based on how much we can produce and how much the average person consumes. Of course we’d like to supply more, but there’s a limitation of how long it takes to scale up.”
While new producers will help address the issue long term, say Moeller, one way Health Canada can better address it now is to issue sales licenses to those already licensed to produce and increase production licenses for those already selling to patients. There are currently eight producers still awaiting a sale license to the public.
“The quickest way to get production online would be to approve the sale license for a bunch of the producers they’ve already got. Approving a new producer means they are approved for production only. It’s probably another year before they’re going to be selling product, so it doesn’t solve any of the short term problems to approve new producers. Additional capacity for existing producers and approving sales licenses for production-only producers is going to be the quickest route to solve the supply shortage at the moment.”
As for their own expansion, Moeller says Health Canada’s response has actually been rapid. They had an inspection on the new space in the past few weeks and he says they expect approval to grow in the new rooms very soon.
Even if there is an end to product shortages in sight, for patients who rely on accessing cannabis through the legal system, these shortfalls show a serious issue with how well the current access program functions. They also highlight why dispensaries, both online and brick-and-mortar, continue to be in such high demand. As long as patients who take the time to access the legal system still can’t find the products they need consistently the stop-gap offered by the ‘grey market’ will continue to serve a purpose.
‘People in this community don’t want these popping up all over the place’
By Andrew Kurjata, CBC News Posted: Jan 10, 2017 4:11 PM PT Last Updated: Jan 10, 2017 4:11 PM PT
Prince Rupert’s mayor and council are hoping to ban all marijuana shops from the city until January 1, 2018.
“This gives us the opportunity to take our time, research what other communities are doing, figure out what the rules are going to be federally,” Mayor Lee Brain told CBC Daybreak North host Carolina de Ryk.
“And once it becomes legalized, then we’ll be able to make rules around that.”
The proposed bylaw would explicitly prevent any business from the commercial production, distribution or sale of marijuana within city limits.
Medicinal marijuana not affected
According to a city spokesperson, the new rules wouldn’t affect licensed users of medicinal marijuana or clinics helping licensed users access medicinal marijuana, as long as the drug was not being sold on site.
Terry Roycroft, president of the Medicinal Cannabis Resource Centre, said the new bylaw wouldn’t stop his plans to open up an office in Prince Rupert.
“That really doesn’t impact our business,” he said. “We deal specifically with the patients who are needing cannabis for any medical treatments that they do.”
Roycroft said he was more surprised by cities that are allowing commercial operations to set up before federal rules come into place.
Raids, fines and crackdowns
Communities across Canada have struggled with the proliferation of marijuana-based businesses ahead of the federal government tabling any laws about legalizing and regulating the drug.
In Vancouver, officials have turned to bylaws and business licences to regulate the industry, handing out fines to those who don’t comply.
In Toronto, Ottawa and Montreal police have cracked down on marijuana storefronts in an attempt to discourage them from setting up in the first place.
Prince Rupert hasn’t faced those problems yet, but Brain hopes explicitly banning commercial marijuana from the city will prevent future problems.
“If people set up a shop now where there’s no real rules and then it becomes legal, they have the risk of being grandfathered in,” he said. “Then we have no control.”
“I’m certain that people in this community don’t want these popping up all over the place.”
A public hearing on the ban is scheduled for January 23.
With files from George Baker and Meera Bains.
‘We are going to see more of that’: Insurer must cover man’s medical marijuana, human rights board says
Keith Doucette, The Canadian Press | February 3, 2017 10:01 AM ET
A human rights board has determined a Nova Scotia man’s prescribed medical marijuana must be covered by his employee insurance plan, a ruling that advocates say will likely have impact nationwide.
Gordon “Wayne” Skinner, of Head of Chezzetcook, suffers from chronic pain following an on-the-job motor vehicle accident, and argued that he faced discrimination when he was denied coverage.
In a decision Thursday, inquiry board chair Benjamin Perryman concluded that since medical marijuana requires a prescription by law, it doesn’t fall within the exclusions of Skinner’s insurance plan.
Perryman ruled the Canadian Elevator Industry Welfare Trust Plan contravened the province’s Human Rights Act, and must now cover his medical marijuana expenses “up to and including the full amount of his most recent prescription.”
“Denial of his request for coverage of medical marijuana … amounts to a prima facie case of discrimination,” the ruling states. “The discrimination was non-direct and unintentional.”
Deepak Anand, executive director of the Canadian National Medical Marijuana Association, said the ruling is significant and could see a number of people apply for coverage through their provincial human rights commissions.
“If they could start to use this avenue to try to get their employers or insurance providers to start covering it, I think that’s going to be significant and we are going to see more of that,” said Anand.
Anand said he knew of one other instance where an insurance company agreed to cover medical marijuana — for University of Waterloo student Jonathan Zaid in 2015.
In the Nova Scotia decision, Perryman said the marijuana was medically necessary for Skinner.
“Since the medical marijuana in this case was prescribed pain management, it seems there is prima facie support for its medical necessity, owing to the fact that conventional prescription pain management drugs are normally eligible for coverage.”
Anand said the reasoning is “significant on its own” because many private and public insurers don’t recognize cannabis and marijuana as a medicine.
I’m elated, I’m still in shock it’s really still sinking in to be honest with you
“They (the inquiry board) are finally recognizing that prescription has some value, which so far the Canadian Medical Association and others have decided not to look at,” he said.
The ruling states the medical marijuana must be purchased from a producer licensed by Health Canada or a person legally authorized to produce for Skinner under the Access to Cannabis for Medical Purposes Regulations. The claim must also be supported by an official receipt.
Skinner, a former elevator mechanic with ThyssenKrupp Elevator Canada has been unable to work since the August 2010 accident.
“I’m elated, I’m still in shock it’s really still sinking in to be honest with you,” Skinner said in a telephone interview from his home outside Halifax.
He argued his own case before the board last October after being denied coverage three times, and said he hoped the inquiry board’s ruling would set a precedent.
“Hopefully this will help other people in similar situations and eliminate the fight that myself and my family have had to endure and the hardship that this has resulted in.”
Perryman found that Skinner’s chronic pain has been under-managed as a result of the denial of coverage, resulting in “profoundly negative effects on the complainant and his family.”
He also found that the plan’s justification for non-coverage was “wholly inadequate.”
“There was no evidence presented to suggest that premiums would have to be increased or that the financial viability of the plan would be threatened,” he wrote.
The Canadian Life and Health Insurance Association wouldn’t comment on Skinner’s case, but said in general it’s up to employers to decide if they want to cover medical marijuana under their group medical plan.
“We do not anticipate any impact on group benefit plans as each plan is unique, but will be reviewing the ruling,” the association said in an email.
For his part, Skinner said the human rights ruling has lifted a large weight from his shoulders.
“Just to have that security of knowing that these medications that are absolutely necessary for me to have any functionality are going to be provided for, just alleviates so much stress and hardship on my family,” he said.